Evaluating and improving antibiotic prescribing in outpatient settings is important. According to the Centers for Disease Control and Prevention, approximately 80% of antibiotic prescriptions are written in the outpatient setting, and 30% of all outpatient antibiotic prescriptions are inappropriate \[[@CIT0001]\]. These inappropriate antibiotic prescriptions contribute to adverse events and increase health care costs \[[@CIT0002]\]. In response, the National Action Plan for Combating Antibiotic-Resistant Bacteria targeted a 50% reduction in inappropriate outpatient antibiotic use by 2020 \[[@CIT0003]\].

Clinical practice guidelines (CPGs) are an existing tool designed to improve patient care. Several CPGs have been specifically written to optimize antibiotic prescribing for common infectious (and noninfectious) conditions \[[@CIT0004]\]. The Infectious Diseases Society of America (IDSA) published a CPG on the treatment of acute uncomplicated cystitis in women on March 1, 2011, focusing on avoidance of fluoroquinolones (FQs) for uncomplicated urinary tract infections (UTIs) and short courses of antibiotics \[[@CIT0006]\]. This information was rapidly incorporated into UpToDate, the Centers for Disease Control and Prevention (CDC) website, and review articles in *American Family Physician* and the *New England Journal of Medicine* (NEJM) \[[@CIT0007]\]. In 2015 and 2016, the American Board of Internal Medicine Foundation's "Choosing Wisely" campaign, the American Urogynecologic Society, and the Food and Drug Administration (FDA) also released guidance to avoid FQ prescriptions for uncomplicated UTIs when reasonable alternatives exist \[[@CIT0011], [@CIT0012]\].

The aims of this study were to evaluate the impact of the IDSA CPG on national antibiotic prescribing practices for uncomplicated UTIs in younger women. Using a large administrative data set, we examined inappropriate antibiotic prescribing, as defined by antibiotic class and treatment duration, for time period before and after release of the IDSA CPG.

METHODS {#s5}
=======

Data Source and Study Design {#s6}
----------------------------

We used the Truven Health Analytics *MarketScan Commercial Claim and Encounters Database* (MarketScan) database to perform a retrospective observational cohort study of uncomplicated UTIs in younger women treated as outpatients between January 1, 2009, and December 31, 2013. The MarketScan database contains administrative claims from all 50 states and approximately 100 different employer-sponsored health insurance plans. The database contains medical claims data from inpatient and outpatient sources and outpatient pharmacy claims. Encrypted patient-level identifiers allow enrollees to be tracked over time.

Case Selection and Definitions {#s7}
------------------------------

We selected our inclusion criteria based on the IDSA uncomplicated UTI CPG \[[@CIT0006]\]. Specifically, we queried the outpatient and pharmacy claims files for women age 18--44 years who had an *International Classification of Diseases, Ninth Revision, Clinical Modification* (ICD-9-CM) diagnosis code of urinary tract infection (595.0), unspecified cystitis (595.9), or uncomplicated cystitis (599.0). We defined the index UTI date as the first service date coded for UTI. We searched office visit claims and non--office visit laboratory claims (eg, urinalysis without an associated visit). We required that women coded for UTI had an accompanying paid antibiotic prescription within +/- 5 days of the index UTI date with a days' supply greater than 0 days. We required medical and pharmacy enrollment for at least 6 months before and 30 days after the index UTI date.

Exclusion Criteria {#s8}
------------------

We conservatively excluded women aged 45 years or older to focus on the premenopausal population. We excluded women coded for the acute and semi-acute infectious conditions within 6 months before or 14 days after the index UTI date based on a study from Dubberke et al. \[[@CIT0013]\]. We excluded women coded for several chronic conditions diagnosed from 6 months before to 1 month after the index UTI date ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). We specifically excluded chronic conditions diagnosed after the index UTI date to remove bias because these conditions were almost certainly present, but not yet diagnosed, on the index UTI date. As some conditions may not be coded, we also excluded individuals based on medications associated with the above conditions or with underlying urologic abnormalities within 6 months before the index UTI date ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). We also excluded women who received intravenous antibiotics as initial therapy, as these cases would not be consistent with uncomplicated infection. Subsequent UTIs were excluded from the analysis.

As the CPG was focused on nonpregnant women, we excluded pregnant women in the 6 months before or the 6 months after our index UTI date based on the study by Kuklina et al. ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}) \[[@CIT0014]\]. We also excluded women coded for a UTI who did not meet inclusion criteria (eg, UTI diagnosed during a hospitalization) within 6 months before the index UTI date as this may represent women with recurrent UTIs or providers may use prior culture results to inform empiric antibiotic selection for subsequent infections. Similarly, we required that all included women have at least a 6-month period free of a UTI before enrollment to further exclude women with recurrent UTIs. Finally, we excluded women with hospitalizations within 90 days before the index UTI date, as these health care exposures may have placed individuals at higher risk for infections with multidrug-resistant pathogens.

Patient Characteristics {#s9}
-----------------------

We collected patient age and comorbidity information. Comorbidities identified in the 6 months before the index UTI were defined using the Elixhauser comorbidity algorithm.

Antibiotic Appropriateness Definitions {#s10}
--------------------------------------

We defined antibiotic appropriateness based on the IDSA CPG in 2 ways: class and duration \[[@CIT0006]\]. First, we evaluated appropriateness by antibiotic class. Appropriate antibiotics included firstline agents (fosfomycin, nitrofurantoin, and trimethoprim-sulfamethoxazole \[TMP-SMX\]); second-line agents (fluoroquinolones and β-lactam antibiotics) were considered inappropriate. Antibiotics not listed as first- or second-line antibiotics were categorized as "other." The other category was then split into 2 separate categories: "other combined" and "other alone." Other combined included other agents that were combined with a first- or second-line agent. Other alone included antibiotics without an accompanying first- or second line-agent. Other combined was not mutually exclusive, so a patient who received an antibiotic prescription for ciprofloxacin and azithromycin counted as an FQ prescription and an other combined prescription. Antibiotic prescriptions were considered the appropriate class if the claim was for a firstline therapy alone or a firstline therapy combined with an other antibiotic. This combination was conservatively deemed appropriate because we were unable to rule out the possibility that the other antibiotic was prescribed for a legitimate reason. However, prescriptions for 2 firstline therapies, a second-line therapy, or another other alone category were considered inappropriate.

Second, we evaluated antibiotic appropriateness by treatment duration according to the IDSA CPG. Appropriate prescription durations were defined as 1 day for fosfomycin, 3 days for FQ and TMP-SMX, 5 days for nitrofurantoin, and 3--7 days for β-lactams. All other antibiotic treatment durations were considered inappropriate. Antibiotic prescriptions without clearly established treatment durations for UTIs were excluded from these analyses. If the patient received 1 appropriate treatment duration and 1 inappropriate treatment duration, then the antibiotic treatment duration was considered inappropriate.

Statistical Analysis {#s11}
--------------------

We compared the demographic characteristics of patients before and after the release of the IDSA CPG. We plotted histograms of antibiotic treatment duration (in days' supply) to evaluate variation in antibiotic prescribing by antibiotic agent. Rates of inappropriate antibiotic prescriptions by class and treatment duration before and after the CPG were compared via chi-square statistics. However, our main outcome was to evaluate temporal trends in the rates of inappropriate antibiotic prescriptions using interrupted time series regression models. Analyses were stratified by class and duration. We utilized the approach outlined by Bernal et al. to determine if guidelines were associated with the level and/or trend in rates of antibiotic prescribing \[[@CIT0015]\]. To correct for the presence of autocorrelation, we used the Newey-West estimator to produce robust standard errors \[[@CIT0016]\]. Several models for the interrupted time series analysis were explored, and the best-fitting one (based on Akaike information criterion and adjusted *R*^2^) was used in the final analysis. The Supplementary Data provide a more detailed summary of the regression model specifications. *P* values of less than .05 were considered statistically significant.

RESULTS {#s12}
=======

We identified 1 921 035 women aged 18--44 years with an ICD-9-CM diagnosis code for UTI between January 1, 2009, and December 31, 2013. After applying inclusion and exclusion criteria to exclude patients with recent hospitalizations, infections, procedures, urologic abnormalities, pregnancy, and significant underlying comorbidities, the final cohort consisted of 654 432 women coded for an index UTI ([Figure 1](#F1){ref-type="fig"}). Patient characteristics before and after the guidelines were similar overall ([Table 1](#T1){ref-type="table"}).

###### 

Characteristics of Women Aged 18--44 Years Coded for Uncomplicated Urinary Tract Infection With Concurrent Antibiotic Prescription(s)

                                                          Before Guidelines (n = 307 609), No. (%)   After Guidelines (n = 346 823), No. (%)
  ------------------------------------------------------- ------------------------------------------ -----------------------------------------
  Age, mean (SD), y                                       31.16 (8.14)                               30.18 (8.32)
  Female sex                                              307 609 (100)                              346 823 (100)
  Comorbidities                                                                                      
   Alcohol abuse                                          728 (0.24)                                 1079 (0.31)
   Anemia deficiency                                      824 (0.27)                                 846 (0.24)
   Arthritis (rheumatoid) and collagen vascular disease   207 (0.07)                                 276 (0.08)
   Chronic blood loss anemia                              29 (0.01)                                  48 (0.01)
   Congestive heart failure                               17 (0.01)                                  16 (0.00)
   Chronic pulmonary disease                              1660 (0.54)                                1903 (0.55)
   Coagulopathy                                           63 (0.02)                                  65 (0.02)
   Depression                                             4355 (1.42)                                5174 (1.49)
   Drug abuse                                             812 (0.26)                                 1436 (0.41)
   Hypertension                                           3172 (1.03)                                3231 (0.93)
   Hypothyroidism                                         1732 (0.56)                                2083 (0.60)
   Liver disease                                          48 (0.02)                                  61 (0.02)
   Fluid and electrolyte disorders                        76 (0.02)                                  80 (0.02)
   Other neurological disorders                           498 (0.16)                                 608 (0.18)
   Obesity                                                5313 (1.73)                                7370 (2.13)
   Paralysis                                              33 (0.01)                                  42 (0.01)
   Peripheral vascular disease                            17 (0.01)                                  23 (0.01)
   Psychoses                                              6494 (2.11)                                7400 (2.13)
   Pulmonary circulation disease                          46 (0.01)                                  41 (0.01)
   Valvular disease                                       107 (0.03)                                 116 (0.03)
   Weight loss                                            1340 (0.44)                                1485 (0.43)

Data are reported as No. (%) unless otherwise specified.

![Cohort selection flow chart. ^a^See [Supplementary Tables 1 and 2](#sup1){ref-type="supplementary-material"} for excluded conditions and medications. ^b^This exclusion criterion was applied to eliminate multidrug-resistant pathogens or empiric antibiotic selection based on prior cultures. ^c^See [Supplementary Table 3](#sup1){ref-type="supplementary-material"} for codes used to exclude pregnancy. Abbreviations: ICD-9-CM, *International Classification of Diseases, Ninth Revision, Clinical Modification*; IV, intravenous; UTI, urinary tract infection.](ofy19801){#F1}

In our cohort of 654 432 women, we identified a total of 665 120 antibiotic prescriptions. Fluoroquinolones represented 284 744 (43%) prescriptions and were the most commonly prescribed antibiotics both before and after the release of the IDSA CPG ([Table 2](#T2){ref-type="table"}). There was a slight reduction in the percentage of FQ (44% vs 42%) and trimethoprim-sulfamethoxazole (TMP-SMX; 28% vs 27%) prescriptions after the guidelines were released, whereas there were slight increases in the percentage of nitrofurantoin (22% vs 24%) prescriptions after the guideline release.

###### 

Frequency of Common Antibiotic Prescriptions Associated With Urinary Tract Infection Claims Before and After the Release of the IDSA Clinical Practice Guideline

  Antibiotic Class                Before IDSA Guideline (n = 313 405), No. (%)   After IDSA Guideline (n = 351 715), No. (%)   *P* Value
  ------------------------------- ---------------------------------------------- --------------------------------------------- -----------
  Fluoroquinolone                 138 033 (44.04)                                146 711 (41.71)                               \<.001
  Trimethoprim-sulfamethoxazole   87 271 (27.85)                                 96 622 (27.47)                                \<.001
  Nitrofurantoin                  68 639 (21.90)                                 85 599 (24.34)                                \<.001
  Beta-lactams                    14 470 (4.62)                                  18 752 (5.33)                                 \<.001
  Fosfomycin                      55 (0.01)                                      48 (0.01)                                     .194
  Other combined                  1193 (0.38)                                    1297 (0.37)                                   .363
  Other alone                     862 (0.28)                                     883 (0.25)                                    .045

The list is not exclusive and includes a combined category; therefore, the total will be slightly over 100%. "Other combined" was defined as nonlisted antibiotic prescriptions combined with a listed antibiotic or 2 nonlisted antibiotics. "Other alone" was defined as a single antibiotic prescription of a nonfirstline or non-second-line antibiotic agent.

Abbreviation: IDSA, Infectious Diseases Society of America.

There was significant variation in the treatment duration for common antibiotic prescriptions for uncomplicated UTI ([Figure 2](#F2){ref-type="fig"}). Providers tended to prescribe antibiotics for 3, 5, 7, or 10 days for first- and second-line UTI antibiotics, with the highest proportion at 7 days. Specifically, 35% of FQ prescriptions, 31% of TMP-SMX, 66% of nitrofurantoin, and 42% of beta-lactam antibiotics were prescribed for 7 days. Only 21% of FQ prescriptions, 26% of TMP-SMX prescriptions, and 16% of nitrofurantoin perceptions were for guideline-recommended durations.

![Antibiotic treatment duration for the most common antibiotics used to treat urinary tract infections. Duration truncated to 14 days. Appropriate treatment durations according to the clinical practice guideline are as follows: 3 days for fluoroquinolones, 3 days for trimethoprim/sulfamethoxazole, 3--7 days for beta-lactam antibiotics, and 5 days for nitrofurantoin; each of the guideline-endorsed treatment durations is denoted by a red arrow.](ofy19802){#F2}

We observed modest improvements in antibiotic prescribing after the guideline release ([Table 3](#T3){ref-type="table"}). Importantly, nonfirstline agent prescriptions represented almost half of antibiotic prescriptions, and treatment durations were inappropriate about three-quarters of the time.

###### 

Appropriateness of Antibiotic Prescriptions Associated With Urinary Tract Infection Claims Before and After the Release of the IDSA Clinical Practice Guideline

  ------------------------------------------------------------------------------------------------------------------
  Antibiotic Prescribed                              Before Guideline\         After Guideline\          *P* Value
                                                     (n = 313 405), No. (%)    (n = 351 715), No. (%)    
  -------------------------------------------------- ------------------------- ------------------------- -----------
  Inappropriate agent                                153 123 (49.78)           165 958 (47.85)           \<.001

  Inappropriate duration                             238 016 (77.38)           262 621 (75.72)           \<.001

   Fluoroquinolones (non-3-d regimen)                108 414/138 033 (78.54)   115 838/146 711 (78.96)   .007

   Nitrofurantoin (non-5-d regimen)                  59 114/68 639 (86.12)     70 778/85 599 (82.69)     \<.001

   Trimethoprim/sulfamethoxazole (non-3-d regimen)   65 821/87 354 (75.35)     70 114/96 703 (72.50)     \<.001

   Beta-lactams (non-3--7-d regimen)                 4955/11 678 (42.43)       6126/15 718 (38.97)       \<.001
  ------------------------------------------------------------------------------------------------------------------

"Inappropriate agent" was defined as a nonfirstline antibiotic prescription. "Inappropriate duration" was defined as a nonendorsed treatment duration.

Abbreviation: IDSA, Infectious Diseases Society of America.

The interrupted time series analysis revealed that the IDSA CPG was associated with a statistically significant change in inappropriate prescribing by class by --0.110% per month (95% confidence interval \[CI\], --0.144 to --0.075; *P* \< .01). [Figure 3A](#F3){ref-type="fig"} depicts the rate of prescription of inappropriate class of antibiotics for treatment of uncomplicated UTI, along with the best-fitting interrupted time series model. Nonlinear regression discontinuity analysis models were also explored and are described in detail in the Supplementary Data ([Supplementary Table 4](#sup1){ref-type="supplementary-material"} and [Supplementary Figures 1 and 2](#sup1){ref-type="supplementary-material"}).

![ Interrupted time series analysis evaluating inappropriate antibiotic prescribing for uncomplicated urinary tract infections in younger women by class and treatment duration, before and after release of the Infectious Diseases Society of America clinical practice guideline in March 2011. The dashed red line corresponds to the release of the clinical practice guideline. The black lines demonstrate the percentage of inappropriate prescriptions. The solid red lines represent before and after trend lines from the time series analysis.](ofy19803){#F3}

The IDSA CPG was also associated with a statistically significant change in the rate of antibiotic prescriptions of inappropriate duration for uncomplicated UTI by --0.037% per month (95% CI, --0.068 to --0.007; *P* \< .05), as measured by the best-fitting interrupted time series model. [Figure 3B](#F3){ref-type="fig"} depicts the rate of prescriptions of antibiotics for an inappropriate duration, along with the best-fitting interrupted time series model. [Supplementary Table 5](#sup1){ref-type="supplementary-material"} summarizes the various regression models used to explore inappropriate duration.

DISCUSSION {#s13}
==========

In our cohort of more than 600 000 healthy women with uncomplicated UTIs, we observed that almost half of antibiotic prescriptions were for non-guideline-recommended antibiotics. Furthermore, \>75% of antibiotic prescriptions for UTIs from 2009--2013 had treatment durations that were not consistent with a CPG endorsed by the CDC and recommended in UpToDate. We also found that CPGs were not associated with clinically relevant impact on provider antibiotic prescribing behavior.

These results are particularly worrisome given the recent FDA black box warning to clinicians to avoid FQs for uncomplicated infections. It is well established that FQs are associated with higher risks of infections and colonization with multidrug-resistant bacterial infections, including *Clostridium difficile* \[[@CIT0017]\]. FQs also have other notable side effects, such as tendonitis, delirium, and cardiac complications \[[@CIT0021]\]. However, FQs have been historically popular with clinicians, representing 49% of all antibiotic prescriptions in outpatient settings between 2002 and 2011 \[[@CIT0024]\]. This high utilization places patients at high risk for adverse events and also likely facilitates the development of FQ-resistant pathogens \[[@CIT0025], [@CIT0026]\].

The publication of guideline recommendations may not be sufficient to meaningfully reduce inappropriate antibiotic use. Two smaller studies, involving a total of 3 outpatient clinics, also demonstrated poor adherence to the IDSA CPG for UTIs \[[@CIT0027], [@CIT0028]\]. Grigorian et al. evaluated 1546 visits for UTI in 2 private family medicine clinics associated with an academic medical center. They found that FQs were the most commonly prescribed antibiotic and that antibiotic treatment durations were frequently longer than recommended. Similarly, Kim et al. used chart review to evaluate 61 patients at a university-based internal medicine clinic; they found an overall guideline adherence rate of 34%. Notably, both studies were small, involved only academic medical center or faculty clinics, and performed less robust statistical analyses. In terms of other conditions, longitudinal data from UK primary care providers between 1995 and 2011 found mixed results from clinical practice guidelines alone, with antibiotic prescriptions for sore throat declining from 77% to 62% and antibiotic prescriptions for viral otitis media increasing from 77% to 85% \[[@CIT0029]\]. A national analysis of outpatient antibiotic prescribing trends in the United States between 2006 and 2010 demonstrated a very slight reduction in antibiotic use \[[@CIT0030]\]. More recent data from Express Scripts Holding Company, the largest pharmacy benefits manager in the United States, did not identify substantial reductions in outpatient antibiotic prescribing practices between 2013 and 2015 \[[@CIT0031]\].

Specific interventions are likely required to improve antibiotic prescribing practices. National quality improvement initiatives have been released by the Joint Commission and the CDC to improve antibiotic prescribing practices in hospital settings \[[@CIT0032], [@CIT0033]\]. The CDC's recently published core elements of outpatient antimicrobial stewardship highlight that clinics should demonstrate commitment to improve antibiotic prescribing practices by implementing at least 1 core policy to improve antibiotic prescribing practices, tracking and reporting antibiotic utilization, and providing education and expertise to clinicians in regards to antibiotic prescribing practices \[[@CIT0034]\]. Active participation in antibiotic stewardship programs will be essential to improve antibiotic utilization, provide better patient care, and combat antimicrobial resistance.

Outpatient antimicrobial stewardship activities have demonstrated improvement in patient care. In a systematic review of outpatient antimicrobial stewardship interventions by Drekonja et al., the following antimicrobial stewardship interventions were effective: provider and/or patient education, provider feedback, guidelines, delayed prescribing, communication skills training, antibiotic restrictions, decision support tools, financial incentives, and rapid diagnostic tests \[[@CIT0035]\]. Hecker et al. were able to improve adherence to UTI guidelines from 44% to 82% in the emergency department via an electronic UTI order set \[[@CIT0036]\]. Other interventions have largely focused on reducing inappropriate antibiotic prescribing for upper respiratory tract infections. Meeker et al. reduced inappropriate antibiotic prescribing by 20% with a simple intervention: displaying a signed poster by providers committing to prescribing antibiotics appropriately \[[@CIT0037]\]. This same group identified additional improvements in antibiotic prescribing by requiring providers to document justifications for antibiotic prescriptions that were outside of the guidelines and by providing benchmarking and feedback in regards to provider antibiotic prescribing performance \[[@CIT0038]\]. However, it is unclear how well some of these interventions, which focus on eliminating inappropriate antibiotic prescribing for nonbacterial conditions, will be applicable to UTIs, for which providers should be focused on optimizing antibiotic selection and treatment duration.

Our study has several limitations. First, we used an insurance claims database, which precludes the ability to link antibiotic prescriptions to a provider or laboratory visit. We restricted antibiotic prescriptions to be temporally associated with the visit coded for UTI, so we assume that the diagnosis and antibiotic choice are linked. However, it is possible that the antibiotic was prescribed for a different condition. We believe this is unlikely given that \>99.5% of antibiotic prescriptions captured in our data set involve classes commonly used to treat uncomplicated UTI. Second, ICD-9-CM diagnosis codes to identify UTIs have not been validated in the outpatient setting. It is possible that some of these visits coded for UTIs were for other conditions such as asymptomatic bacteriuria and pyelonephritis. However, we believe that these data demonstrate provider antibiotic selection for perceived uncomplicated UTIs based on coding. Furthermore, as pyelonephritis is much less frequent than UTI (with an estimated ratio of 1 case of pyelonephritis per 28 cases of cystitis), misclassification bias would likely be modest and stable over time \[[@CIT0039]\]. Third, our analyses only captured antibiotic prescriptions with an associated ICD-9-CM code for UTI. Antibiotic prescriptions from providers who prescribed an antibiotic based on a telephone call but did not bill for the encounter were not captured in our database. These "phantom prescriptions" \[[@CIT0040]\] may be different than those captured via laboratory claims and office visits in the database. Fifth, it is possible that antibiotic prescribing of providers has changed since the study period (2009--2013). We restricted the study period to earlier years to avoid later time periods that coincide with additional CPGs, such as the American Urologic Society and the American Board of Internal Medicine \[[@CIT0012]\]. Sixth, we do not know provider rationale for antibiotic selection from the claims data. Some providers may have appropriately selected a second-line agent due to antibiotic allergies or local antibiotic resistance patterns. Seventh, although the CPG did not show a meaningful improvement in antibiotic prescribing during the study period, it is possible that we would find an impact if we expanded our time frame by several years.

CONCLUSIONS {#s14}
===========

The vast majority of antibiotic prescriptions for uncomplicated UTIs have been written for a non-guideline-endorsed treatment agent and/or duration. FQ, a nonfirstline agent with an FDA black box warning, was the most commonly prescribed antibiotic. Clinical practice guidelines endorsed and disseminated by the CDC, UpToDate, and an NEJM review article had no clinically relevant impact on antibiotic prescribing practices. Antimicrobial stewardship interventions are necessary to improve outpatient antibiotic prescribing for uncomplicated UTIs.

Supplementary Data {#s15}
==================

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

###### 

Click here for additional data file.
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